Allogene Therapeutics Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | – | – | – | – | – | – | – | – | 100.0% | 100.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 10.2% | 5,343.2% | 119,836.7% | 8,317.6% | 98,616.4% | 5,638.4% | 129,879.6% | 7,038.3% | 12,380.0% | 17,240.9% | 16,236.4% | – | 16,159.1% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -16,136.4% | – | -16,059.1% | – | – | – | – | – | – | – | – | 100.0% | -699.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 143.9% | 118,840.9% | 119,836.7% | 105,849.0% | 98,616.4% | 66,477.9% | 129,879.6% | 160,466.0% | 267,460.0% | 281,990.9% | 208,986.4% | – | 237,540.9% | – | – | – | – | – | – | – | – | 662.1% | 2,578.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 42.7% | 42,688.6% | 38,773.5% | 39,139.2% | 32,618.0% | 22,684.9% | 38,565.3% | 44,685.1% | 62,946.7% | 84,200.0% | 77,459.1% | – | 78,486.4% | – | – | – | – | – | – | – | – | 449.1% | 1,345.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 186.6% | 161,529.5% | 158,610.2% | 144,988.2% | 131,234.4% | 89,162.8% | 168,444.9% | 205,151.1% | 330,406.7% | 366,190.9% | 270,209.1% | – | 299,868.2% | – | – | – | – | – | – | – | – | 1,111.2% | 3,186.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -86.6% | -161,429.5% | -158,510.2% | -144,888.2% | -131,134.4% | -89,062.8% | -168,344.9% | -205,051.1% | -330,306.7% | -366,090.9% | -286,345.5% | – | -315,927.3% | – | – | – | – | – | – | – | – | -1,011.2% | -3,886.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 1.3% | 1,418.2% | 802.0% | 364.7% | 232.8% | 366.3% | 2,044.9% | 2,802.1% | 1,220.0% | – | 0.0% | – | 0.0% | – | – | – | – | – | – | – | – | 7.4% | 28.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -86.1% | -161,218.2% | -159,563.3% | -146,800.0% | -130,901.6% | -86,961.6% | -169,689.8% | -201,802.1% | -333,226.7% | -360,145.5% | -283,122.7% | – | -295,454.5% | – | – | – | – | – | – | – | – | -919.8% | -3,566.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -1.3% | -1,418.2% | -802.0% | -8,682.4% | -232.8% | -366.3% | -2,044.9% | -3,248.9% | -1,220.0% | -17,172.7% | -28,204.5% | – | 15,962.4% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -86.1% | -161,218.2% | -159,563.3% | -146,800.0% | -130,901.6% | -86,961.6% | -169,689.8% | -201,802.1% | -333,226.7% | -360,145.5% | -283,122.7% | – | -295,454.5% | – | – | – | – | – | – | – | – | -919.8% | -3,566.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -81.6% | -156,754.5% | -154,808.2% | -138,482.4% | -124,849.2% | -82,688.4% | -161,812.2% | -195,274.5% | -321,536.7% | -343,586.4% | -266,886.4% | – | -279,295.5% | – | – | – | – | – | – | – | – | -855.4% | -3,287.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.